



Press Release

Granules India's Revenue increases 11% to Rs. 346 Cr.; Net Profit surges 19% to Rs. 27 Cr.

Hyderabad, July 23, 2015: Granules India Ltd., a fast growing pharmaceutical manufacturing company, announced financial results for its First Quarter ended 30th June, 2015.

Consolidated Q1FY16 Financial Highlights

- Revenue: Rs. 346 Cr., an increase of 11% compared to Rs. 311 Cr. in Q1FY15
- EBITDA: Rs. 64 Cr., an increase of 20% compared to Rs. 53 Cr. in Q1FY15
- Net Profit: Rs. 27 Cr., an increase of 19% compared to Rs. 23 Cr. in Q1FY15

The Company's profitability margins continued to strengthen compared to the corresponding quarter in the previous financial year and sequential quarter. The Company's focus on operational efficiency helped improved EBITDA margin by 137 basis points compared to the Q1FY15. During this quarter PAT margin has also witnessed an improvement of 50 basis points compared to the same period previous year.

The Company's standalone sales during the quarter were Rs. 325 Cr., an increase of 28% from the same quarter previous year. EBITDA and PAT increased by 33% and 36% to Rs. 66 Cr. and Rs. 30 Cr. compared to Q1FY15.

The Board of Directors has approved the issue of 1,86,56,000 warrants on preferential basis to M/s. Tyche Technologies Pvt. Ltd., a promoter group Company, subject to approval of the shareholders, at a price arrived at in accordance with the SEBI (ICDR) Regulations, 2009.

"The first quarter of the financial year of 2016 had been encouraging as we continued to deliver strong results by focussing on operational efficiency and showing improvement in margin profile of the Company. During this quarter, we have further strengthened our footings towards introduction of newer molecules to increase our product portfolio. In addition, our PFI expansion at the Gagillapur facility with 4000 TPA has successfully completed trial runs and we expect to ramp up production in that block throughout the year." said Mr. C Krishna Prasad, Chairman & Managing Director of Granules India.



About Granules India Ltd.

(BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

Granules has the largest PFI facility in the world with an industry leading 6 ton batch size. The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.

Granules has strengthened its advantages through its Operational Excellence (OE) department which looks at every step of the manufacturing process in order to gain efficiencies and has also implemented systems that have standardized quality and reduced variation. The Company's OE program is regularly cited by MNCs as a "best in class" program and is the comparative advantage that lets Granules provide world-class quality products at a lower cost than its competitors. The adoption of the OE philosophy by Granules has earned it several recognitions including The Economic Times Manufacturing Excellence Awards 2011.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

Contacts:

Govindan JM
Genesis Burson-Marsteller
+91 9703700884
Govindan.JM@bm.com

Appendix